[go: up one dir, main page]

PE20020147A1 - Derivado de caseina como inhibidor de la adhesion de agentes patogenos a la piel - Google Patents

Derivado de caseina como inhibidor de la adhesion de agentes patogenos a la piel

Info

Publication number
PE20020147A1
PE20020147A1 PE2001000702A PE2001000702A PE20020147A1 PE 20020147 A1 PE20020147 A1 PE 20020147A1 PE 2001000702 A PE2001000702 A PE 2001000702A PE 2001000702 A PE2001000702 A PE 2001000702A PE 20020147 A1 PE20020147 A1 PE 20020147A1
Authority
PE
Peru
Prior art keywords
casein
caseinoglycomacropeptide
adhesion
derivative
inhibitor
Prior art date
Application number
PE2001000702A
Other languages
English (en)
Inventor
Jean-Richard Neeser
Isabelle Auzanneau
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169257&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of PE20020147A1 publication Critical patent/PE20020147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/986—Milk; Derivatives thereof, e.g. butter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN DERIVADO DE CASEINA SELECCIONADO DE CASEINOGLICOMACROPEPTIDO (CGMP), DERIVADO GLICOSILADO O PRODUCTOS OBTENIDO POR HIDROLISIS DE LOS CASEINOGLICOMACROPEPTIDO EN FORMA DE SALES DE CALCIO O SODIO. CASEINOGLICOMACROPEPTIDO (CGMP) ES UN MACROPEPTIDO FORMADO POR LA ACCION DEL CUAJO O DE QUIMOSINA SOBRE KAPPA-CASEINAS DE LA LECHE. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE DE 0.01% A 10% DE PREFERENCIA ENTRE 0.5% A 5% EN PESO DEL DERIVADO DE CASEINA . EL DERIVADO DE CASEINA ES CAPAZ DE ESTABILIZAR Y/O REGULAR LA FLORA PATOGENA DEL SISTEMA CUTANEO INHIBIENDO LA ADHESION DE AGENTES PATOGENOS TALES COMO STREPTOCOCCUS PYOGENES, TRICHOPHYUTON RUBRUM, PITYROSPORUM OVALE, M. FURFUR, CANDIDA ALBICANS Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA CUTANEO COMO COMPLICACIONES INFECCIOSAS, POLIDERMATITIS, DERMATITIS , DERMATOFITOSIS, CANDIDIASIS, INFECCIONES ESTREPTOCOCCICAS Y MICOTICAS
PE2001000702A 2000-07-14 2001-07-13 Derivado de caseina como inhibidor de la adhesion de agentes patogenos a la piel PE20020147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115274 2000-07-14

Publications (1)

Publication Number Publication Date
PE20020147A1 true PE20020147A1 (es) 2002-02-26

Family

ID=8169257

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000702A PE20020147A1 (es) 2000-07-14 2001-07-13 Derivado de caseina como inhibidor de la adhesion de agentes patogenos a la piel

Country Status (14)

Country Link
US (1) US20030161850A1 (es)
EP (1) EP1303295B1 (es)
JP (1) JP2004503597A (es)
AR (1) AR029829A1 (es)
AT (1) ATE339217T1 (es)
AU (1) AU2001287560A1 (es)
CA (1) CA2415918C (es)
DE (1) DE60123067T2 (es)
DK (1) DK1303295T3 (es)
ES (1) ES2272535T3 (es)
PE (1) PE20020147A1 (es)
PT (1) PT1303295E (es)
UY (1) UY26835A1 (es)
WO (1) WO2002005839A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321996D0 (en) * 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
CA2699170A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2011132191A1 (en) 2010-04-21 2011-10-27 Mileutis Ltd. Casein peptide for use in the treatment of uterine infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7786M (es) * 1968-10-07 1970-03-23
FR8087M (es) * 1968-10-08 1970-07-20
US3764670A (en) * 1970-10-28 1973-10-09 Ministry Of Agriculture Polypeptidic anti-biotic substances derived from casein
DE3049038A1 (de) * 1980-12-24 1982-07-15 Marie 8000 München Hauck Mittel zur bekaempfung von hautkrankheiten
US4525351A (en) * 1983-01-11 1985-06-25 Chr. Hansen's Laboratory, Inc. Liquid adherent disinfectant compositions for topical application and method of preparation
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
CH671879A5 (es) * 1987-02-26 1989-10-13 Nestle Sa
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
US5681586A (en) * 1989-03-23 1997-10-28 Gordon; Arthur L. Enzyme-modified soy and soy/casein combination healing compositions
US5166132A (en) * 1989-03-23 1992-11-24 Gordon Arthur L Healing composition employing an enzyme-modified casein
JP2673320B2 (ja) * 1990-01-25 1997-11-05 雪印乳業株式会社 う蝕原菌付着阻止剤
FR2657525B1 (fr) * 1990-01-26 1994-07-29 Dubois Jacques Produits dermo-cosmetiques nouveaux pour le nettoyage et le soin de la peau et/ou des cheveux.
EP0760673A1 (en) * 1994-05-26 1997-03-12 Abbott Laboratories INHIBITION OF ATTACHMENT OF $i(H. INFLUENZAE) TO HUMAN CELLS
WO1998046240A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions

Also Published As

Publication number Publication date
EP1303295A1 (en) 2003-04-23
JP2004503597A (ja) 2004-02-05
DK1303295T3 (da) 2007-01-02
US20030161850A1 (en) 2003-08-28
EP1303295B1 (en) 2006-09-13
DE60123067D1 (de) 2006-10-26
AR029829A1 (es) 2003-07-16
CA2415918A1 (en) 2002-01-24
ATE339217T1 (de) 2006-10-15
DE60123067T2 (de) 2007-04-12
UY26835A1 (es) 2002-01-31
ES2272535T3 (es) 2007-05-01
WO2002005839A1 (en) 2002-01-24
PT1303295E (pt) 2007-01-31
CA2415918C (en) 2010-06-01
AU2001287560A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
BR0111123A (pt) Artigo de confeitaria congelado e processo de preparação do mesmo
CO6300929A2 (es) Composicion oral que contiene amino acidos y sal soluble de calcio
PE20020147A1 (es) Derivado de caseina como inhibidor de la adhesion de agentes patogenos a la piel
TW200715982A (en) Low-lactose partially hydrolyzed infant formula
CL2008003809A1 (es) Composicion en polvo nutricional que comprende carboidratos, lipidos con 0,25 a 2,5% de lecitina, 90 a 99,5% de proteina intacta y 0,5 a 10% de proteina de suero con un grado de hidrolisis de entre 23 y 90%; y composiciones nutricionales para bebes.
CL2022002719A1 (es) Composiciones que comprenden nicotina o sales de nicotina y aerosolización ultrasónica de composiciones que comprenden nicotina o sales de nicotina
CL2013000306A1 (es) Productos de confiteria envasados no congelados para la preparacion de un confite estaticamente congelado que comprende un sistema de proteina coagulada que incluye caseina y proteina de suero donde el sistema de proteina coagulada se puede obtener sometiendo una composicion de proteinas lacteas con un ph entre 5,6 y 6,5 a un tratamiento termico de 80-90 ºc o por sobre 90 º hasta 160 ºc por 1 segundo hasta 60 minutos; y metodo de producción de dicho producto.
AR082587A1 (es) Metodo para la fabricacion de productos dulces congelados y producto obtenido
MX2009006649A (es) Composicion de acido peracetico mejorada.
AR017795A1 (es) Composicion para el cuidado de la piel con capacidad mejorada de hidratacion de la piel
BRPI0603980A (pt) processo para a produção de uma composição flavorizante, e, produto de fermentação tipo queijo cremoso com baixo teor de gordura
AR034551A1 (es) Derivado lacteo que presenta una composicion mineral y de aminoacidos selectivamente modificada, procedimientos para su fabricacion y aplicaciones
ES2193620T3 (es) Productos de almidon expandido biodegradable y metodo de preparacion.
AR108083A1 (es) Composiciones, kits y métodos para mantener la higiene del párpado
AR011783A1 (es) Composiciones liquidas limpiadoras de la piel
Cho New approaches to the control of pathogenic oral bacteria
ATE396147T1 (de) Nanoskalige calciumphosphattabletten
ES2078740T3 (es) Utilizacion como ingrediente activo, en la preparacion de una composicion cosmetica, de por lo menos un peptido purificado que puede obtenerse por hidrolisis de caseina con actividad opioide.
EP2124976A4 (en) WAKE-INHIBITION AND ELIMINATION OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS BY MILKY ACID BACTERIA
PT1313837E (pt) Novas estirpes de lactobacillus paracasei
HRP20050868A2 (en) Small indicator block
BR0209820A (pt) Processo para a preparação de formulações sólidas de 3-hidróxi-3-metilbutirato de sódio
ATE323423T1 (de) Futter welches die nahrungsaufnahme pro zeiteinheit bei hunden verzögert
WO2013093168A9 (es) Materiales nanocompuestos activos basados en sales generadoras de so2 y edta y el procedimiento para su obtención
JP5140426B2 (ja) 齲蝕原因菌に選択的な殺菌剤、齲蝕原因菌を殺菌する方法

Legal Events

Date Code Title Description
FD Application declared void or lapsed